15 November 2021 : Clinical Research
Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis
Xiaobu Lan12ACE*, Kai Mo12ADG, Li Nong12CEF, Yi He12BCD, Yuhong Sun12BDOI: 10.12659/MSM.934275
Med Sci Monit 2021; 27:e934275
Table 2 Chi-squared test of standard-reaching rate of VPA serum concentrations by single-factor analysis.
| Variable | n (Standard concentration) | n (Substandard concentration) | (% of all) | P | |
|---|---|---|---|---|---|
| Age/years | ≤13 | 18 | 5 | 78.3% | 0.015 |
| 14–59 | 17 | 24 | 41.5% | ||
| ≥60 | 21 | 22 | 48.8% | ||
| Sex | Male | 44 | 38 | 53.7% | 0.620 |
| Female | 12 | 13 | 48% | ||
| Daily dose | ≤0.5 | 18 | 10 | 64.3% | 0.020 |
| 0.5–1 | 26 | 37 | 41.3% | ||
| >1 | 12 | 4 | 75% | ||
| Dosage form | Non-sustained release dosage form | 45 | 44 | 50.6% | 0.414 |
| Sustained-release dosage form | 11 | 7 | 61.1% | ||
| Hepatic function | Normal or mild injury | 3 | 2 | 60% | 1.000 |
| Severe injury | 53 | 49 | 52% | ||
| Renal function | Normal or mild injury | 5 | 10 | 33.3% | 0.1120 |
| Moderate to severe | 51 | 41 | 55.4% | ||
| Carbapenems | No | 55 | 34 | 61.8% | 0.0001 |
| Combination | 1 | 17 | 5.6% | ||
| Enzyme inducer drugs | No | 52 | 33 | 61.18% | 0.01 |
| Combination | 4 | 18 | 18.18% |